A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of DNA Vaccine EP-1233 and Recombinant MVA-HIV Polytope Vaccine MVA-mBN32, Separately and in a Combined Prime-Boost Regimen, When Given to Healthy, Vaccinia-Naive, HIV-1-Uninfected Adults.

Trial Profile

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of DNA Vaccine EP-1233 and Recombinant MVA-HIV Polytope Vaccine MVA-mBN32, Separately and in a Combined Prime-Boost Regimen, When Given to Healthy, Vaccinia-Naive, HIV-1-Uninfected Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2012

At a glance

  • Drugs EP 1232 (Primary) ; EP 1233 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Mar 2012 Actual patient number (36) added as reported by ClinicalTrials.gov.
    • 29 Mar 2012 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top